Microwave Ablation Versus Liver Resection For Early Hepatocellular Carcinoma in Patients With Borderline Liver Function

Carcinoma, Hepatocellular Clinical Trial

Official title:

Microwave Ablation Versus Liver Resection For Early Hepatocellular Carcinoma in Patients With Borderline Liver Function

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03766555
• Other study ID #: 2016.205
• Status: Recruiting
• Phase: N/A
• Start date: May 21, 2018
• Est. completion date: July 2025

Study information

• Verified date: February 2023
• Source: Chinese University of Hong Kong
• Contact: Chun Yeung, MSc
• Phone: 35053933
• Email: philipyeung[@]surgery.cuhk.edu.hk
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

We propose a randomized controlled study to compare the treatment efficacy of microwave ablation to liver resection for hepatocellular carcinoma (HCC) in patients with borderline liver function.

Description:

Hepatocellular carcinoma (HCC) is a common cancer and is diagnosed at an earlier stage and with increasing frequency because of the wider implementation of screening programs. Whether liver resection or local ablation should be the first-line treatment in early HCC remains a hot topic for debate. Both are regarded as acceptable curative treatment for early HCC in many international guidelines. Underlying liver function is the key in treatment selection. The general consensus is that liver resection should be the treatment of choice in patients with good liver function while local ablation should be considered in patients with poor liver function. There exists a group of patients with apparently good liver function that harbor significant liver cirrhosis which is not easily picked up by the current assessment or scoring systems. Liver resection in this group of patients is burdened by potentially life-threatening complications and the overall survival is limited by their underlying liver cirrhosis. This is particularly important in early HCC as local ablation is another curative treatment option. In order to improve the prognosis of patients with early HCC, it is important to identify (1) patients with liver dysfunction to the extend that the risk of liver resection will outweigh the survival benefit it provides; (2) the best ablative method for HCC. The investigators propose to carry out a prospective randomized controlled study to compare the treatment outcome of microwave ablation with liver resection in patients with borderline liver function whose HCC that are amendable to both liver resection and microwave ablation.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 76
• Est. completion date: July 2025
• Est. primary completion date: July 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age >18 years
• HCC amendable for both MWA and liver resection
• Liver function of ALBI Grade 2
• Tumour size </= 5cm
• Absence of extrahepatic metastasis
• Absence of radiology evidence of major vascular or bile duct invasion

Exclusion Criteria:

• Informed consent not available
• Patients with ALBI 3, Child-Pugh B or above
• Multifocal tumour
• Presence of portal vein or hepatic artery thrombosis
• Anticipation of concomitant procedures
• Emergency hepatectomy
• Ruptured HCC
• Patients with chronic renal failure
• Pregnant female patients

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Hepatocellular

Intervention

Procedure:
• Microwave ablation
Microwave ablation will be performed in operation theatre under general anesthesia via laparoscopic or open approach according to the tumors' locations. In case of open approach, it will be done via a right subcostal incision with possible upper midline extension was necessary. After diagnostic laparoscopy in laparoscopic approach and exploratory laparotomy in open approach to exclude the presence of extra-hepatic disease, operative ultrasound (Aloka, Tokyo, Japan) will be performed to exclude preoperatively undetected lesion; guide insertion of the microwave applicator; and monitor the whole ablation process. Surrounding organs were cooled by constant irrigation of ice-cold saline to prevent thermal injury. The ablation will be carried out according to the standard protocol with the aim to create a 1cm ablation margin around the tumor. The insertion track will be burnt after ablation in order to prevent bleeding and tumor seeding.
• Liver resection
Liver resection will be performed as described previously. Liver parenchymal transection would be performed with CUSA (cavitron ultrasonic surgical aspirator) and TissueLink (a radiofrequency saline-linked dissecting sealer) in both arms. Vascular staplers would be used to divide major vascular pedicles. Fibrin glue (Tisseel) spray would be applied to the parenchymal cut surface of the liver before closure of abdomen.

Locations

Country	Name	City	State
Hong Kong	Prince of Wales Hospital	Shatin

Sponsors (1)

Lead Sponsor	Collaborator
Chinese University of Hong Kong

Country where clinical trial is conducted

Hong Kong, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall survival	The primary outcome of this study is the overall survival	5 years
Secondary	Disease-free survival	Disease-free survival	5 years
Secondary	Recurrence rate	Liver cancer recurrence rate	5 years
Secondary	Morbidity rate	Morbidity rate	1 year
Secondary	Hospital stay	Hospital length of stay	1 year

External Links

•   Hong Kong Hospital Authority. Hong Kong Cancer Registry. 2012.